Continuing the exploration of the effect of the triple combination therapy on the F508del mutation, Stanke and co-workers analyzed the effects of elexacaftor/tezacaftor/ivacaftor on the expression and maturation of the Phe508del CFTR protein in rectal suction biopsies from 21 cystic fibrosis patients homozygous or compound heterozygous for the mutation. This evidence concerns the gene CFTR and cystic fibrosis.